Chiasma
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Chiasma - overview
Established
2001
Location
Jerusalem, -, Israel
Primary Industry
Pharmaceuticals
About
Chiasma is a biopharmaceutical company focused on developing innovative therapeutics to improve patient outcomes. They specialize in transforming the treatment of chronic diseases through unique delivery systems and formulations. Chiasma, founded in 2001 in Jerusalem, Israel, is a biopharmaceutical company dedicated to improving the lives of patients with chronic diseases. The company was co-founded by Asif Abbas and Marcel Craven.
Chiasma raised USD 102 mn through an IPO in July 2015, offering 6. 4 million shares at USD 16 per share on the NASDAQ, marking a significant milestone in their funding journey. Chiasma specializes in delivering innovative therapeutic solutions, particularly in the biopharmaceutical sector. Their core product offerings focus on advanced drug delivery systems designed to enhance patient compliance and treatment efficacy.
These products address specific challenges in the management of chronic diseases, ensuring patients receive effective therapies while minimizing the complexity of treatment regimens. The company’s solutions cater to various healthcare sectors, demonstrating their adaptability and commitment to patient-centric care. Chiasma operates on a revenue model primarily geared towards pharmaceutical sales, providing access to groundbreaking therapies through specialized distribution channels. Their strategic partnerships with healthcare providers ensure that their innovative products reach patients effectively.
The company's pricing plans are structured to accommodate diverse healthcare systems and patient needs, contributing to a stable revenue flow. Chiasma is focused on expanding its product line with planned launches of new therapies designed to address unmet medical needs in chronic disease management by 2025. The company is strategically targeting expansion into markets in Europe and Asia-Pacific to leverage increasing demand for innovative biopharmaceutical solutions. The funds raised in the recent IPO will support these growth initiatives, facilitating research and development efforts and market entry strategies.
Current Investors
Jerusalem Global Ventures, F2 Ventures, XT Investments
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
chiasmapharma.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.